

Isis Pharmaceuticals' Stanley Crooke Awarded 2013 Distinguished Scientist

October 9, 2013

CARLSBAD, Calif., Oct. 9, 2013 /PRNewswire/ -- Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), has been awarded the 2013 Distinguished Scientist Award by the San Diego section of the American Chemical Society (ACS). The award recognizes Dr. Crooke's contributions in leading Isis Pharmaceuticals, a long-standing leader in drug discovery in the San Diego community. Isis' innovative RNA-based drug discovery technology has created a pipeline of novel antisense drugs to treat a wide variety of diseases.

(Logo: <http://photos.prnewswire.com/prnh/20130807/LA60006LOGO>)

"I am honored to be recognized by the American Chemical Society as this year's distinguished scientist. I am proud to be a part of an organization that strives to advance chemistry across all disciplines and support the local chapter's efforts to increase education and awareness of chemistry among San Diego's future scientists," said Stanley T. Crooke, M.D., Ph.D., chief executive officer and chairman at Isis.

During the last year, Isis has experienced substantial growth in all areas of its business, including the approval of KYNAMRO™, advancement of its product pipeline with positive clinical data in multiple programs, and completion of several successful partnerships that should accelerate discovery and development of drugs to improve the lives of patients and significantly improve the Company's already strong financial position. More information on the award is available at www.sandiegoacs.org.

The Distinguished Scientist Award is bestowed annually by the San Diego Section of the ACS to a scientist that has made outstanding professional contributions. Previous winners of the honor include: Roger Y. Tsien, Julius Rebek, Chi-Huey Wong, K. C. Nicolaou and Barry Sharpless.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 30 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis Pharmaceuticals' business, the therapeutic and commercial potential of Isis' technologies and products in development, Isis' financial position and the commercial potential of KYNAMRO. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. KYNAMRO™ is a trademark of Genzyme Corporation.

SOURCE Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals' Contacts: D. Wade Walke, Ph.D., Vice President, Corporate Communications and Investor Relations, 760-603-2741, or Amy Blackley, Ph.D., Associate Director, Corporate Communications, 760-603-2772